SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025. The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company’s announcement that ...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants provided overw ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW ...

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly misleading investors regarding the viability and efficacy of its gene therapy product RP-A501, particularly in relation to its Phase 2 clinical trial for Danon disease [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Rocket Pharmaceuticals misrepresented the reliability of information regarding the projected timeline and safety of the RP-A501 trial, leading to a false sense of security among investors [2]. - Following the announcement of a Serious Adverse Event (SAE) involving a patient in the trial, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, reflecting a significant loss in market value [3]. Group 2: Company Background - Rocket Pharmaceuticals is described as a fully integrated, late-stage biotechnology company focused on developing gene therapies for rare and severe diseases, emphasizing its commitment to clear clinical endpoints and direct on-target mechanisms of action [1]. Group 3: Legal Proceedings - Shareholders interested in participating in the class action can contact Robbins LLP, which is leading the litigation on a contingency fee basis, meaning no fees or expenses are required from shareholders [4][5].

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) between February 27, 2025, to May 26, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Rondolph Ho v. Rocket Pharmaceuticals, Inc., et al. (Case No. 3:25-cv-10049) has been commenced in the United States District Court ...

28 May 2025 | 9:26AM EDT Rocket Pharmaceuticals Inc. (RCKT): Clinical Hold on Ph. 2 DD Trial Puts Largest Late-Stage Oppy At Risk; Downgrade to Sell w/ $2 PT On Tuesday (5/27), RCKT announced that the FDA placed a clinical hold on its pivotal Ph. 2 Danon disease (DD) trial. The hold was issued on 5/23 after a patient treated in early May experienced capillary leak syndrome that emerged ~1 week after RP-A501 dosing. Although there were some early signs the condition was beginning to improve, the patient subs ...

LOS ANGELES, May 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Rocket investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rocket Pharmaceuticals and its officers or directors following a serious adverse event in a clinical trial that led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an unexpected serious adverse event (SAE) related to its investigational gene therapy RP-A501 for Danon disease, which involved clinical complications from capillary leak syndrome [3]. - Following the SAE, Rocket voluntarily paused further dosing in the Phase 2 pivotal trial, and the FDA placed a clinical hold on the trial for further evaluation [3]. - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3]. Group 2: Market Reaction - The announcement of the SAE resulted in Rocket's stock price falling by $3.94 per share, a decrease of 62.84%, closing at $2.33 per share on May 27, 2025 [3]. Group 3: Legal Context - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in the investigation regarding Rocket Pharmaceuticals [1][4].

Core Viewpoint - Rocket Pharmaceuticals (RCKT) shares fell 62.8% following the announcement of a patient death in a pivotal phase II study for its gene therapy candidate RP-A501, aimed at treating Danon disease [1][2] Company Developments - RCKT has voluntarily paused further dosing in the RP-A501 study after the FDA placed a clinical hold on it [2] - The company is conducting a comprehensive root cause analysis to understand the serious adverse event that led to the patient's death [2] - RCKT is collaborating with the FDA, Independent Data Safety Monitoring Committee, clinical investigators, and scientific experts to ensure patient safety and to restart the study as soon as possible [3] Stock Performance - Year-to-date, RCKT shares have declined 81.5%, significantly underperforming the industry, which has seen a decline of 5.8% [4] Pipeline Setbacks - RCKT has faced setbacks with its pipeline candidates, particularly with Kresladi, which is intended to treat severe leukocyte adhesion deficiency-I (LAD-I) [5] - The FDA issued a complete response letter (CRL) regarding the biologics license application (BLA) for Kresladi, requesting limited additional information on Chemistry Manufacturing and Controls (CMC) [7] - This marks the second request for additional information from the FDA regarding Kresladi's CMC, with the review period extended by three months in February 2024 [7] - The company plans to file a complete BLA to address the CRL later in 2025 [8]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...